Disodium pamidronate (APD) in the treatment of bone metastases.

Authors

  • L Costa Serviço de Medicina I, Hospital de Santa Maria, Lisboa.
  • C Moreira
  • E B da Costa

DOI:

https://doi.org/10.20344/amp.3059

Abstract

Diphosphonates are potent inhibitors of bone resorption, they have been evaluated in several clinical trials for bone metastases. We performed a clinical study to evaluate the therapeutic effect of Disodium Pamidronate over pain and radiologic evolution in bone metastases (Breast Cancer and Multiple Myeloma patients). The results regarding the first 10 patients concluded that there is good drug tolerability and significant analgesic activity in 6 patients, with sclerosis of lytic skull lesions in one breast cancer patient.

Downloads

Download data is not yet available.

How to Cite

1.
Costa L, Moreira C, da Costa EB. Disodium pamidronate (APD) in the treatment of bone metastases. Acta Med Port [Internet]. 1993 Feb. 27 [cited 2024 Nov. 2];6(2):71-3. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/3059

Issue

Section

Arquivo Histórico